Maksymowych, Walter P. http://orcid.org/0000-0002-1291-1755
Thom, Howard
Mørup, Michael F.
Taieb, Vanessa
Willems, Damon
Lyris, Nikos
Gaffney, Karl
Funding for this research was provided by:
UCB Pharma
Article History
Received: 22 March 2024
Accepted: 22 May 2024
First Online: 25 June 2024
Declarations
:
: Walter P Maksymowych: Honoraria/consulting fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB Pharma; research grants from AbbVie, Galapagos, Pfizer, and UCB Pharma; educational grants from AbbVie, Janssen, Novartis, and Pfizer; Chief Medical Officer for CARE ARTHRITIS; Howard Thom: Owns shares in Clifton Insight which has received consulting fees from Argenx, Bayer, BMS, Daiichi-Sankyo, Eisai, Lundbeck, Novartis, Pfizer, Roche, and UCB Pharma; Michael F Mørup: Employee of UCB Pharma; Vanessa Taieb, Damon Willems, Nikos Lyris: Employee of UCB Pharma; shareholder of UCB Pharma; Karl Gaffney: Speakers bureau for AbbVie, Eli Lilly, Novartis, and UCB Pharma; consultant of AbbVie, Eli Lilly, Novartis, and UCB Pharma; Grant/research support from AbbVie, Gilead, Eli Lilly, Novartis, and UCB Pharma.
: This study was non-interventional and based on published secondary data from randomized controlled trials, therefore ethical/institutional review and approval were not required. All included trials obtained informed consent from participants and were conducted in accordance with the Declaration of Helsinki.
: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.